BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28786008)

  • 1. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study.
    Braat AJAT; Prince JF; van Rooij R; Bruijnen RCG; van den Bosch MAAJ; Lam MGEH
    Eur Radiol; 2018 Mar; 28(3):920-928. PubMed ID: 28786008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.
    Prince JF; van Rooij R; Bol GH; de Jong HW; van den Bosch MA; Lam MG
    J Nucl Med; 2015 Jun; 56(6):817-23. PubMed ID: 25931477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
    Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
    Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The superior predictive value of
    Smits MLJ; Dassen MG; Prince JF; Braat AJAT; Beijst C; Bruijnen RCG; de Jong HWAM; Lam MGEH
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):798-806. PubMed ID: 31399801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.
    Elschot M; Nijsen JF; Lam MG; Smits ML; Prince JF; Viergever MA; van den Bosch MA; Zonnenberg BA; de Jong HW
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1965-75. PubMed ID: 24819055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [
    Wagemans MEHM; Braat AJAT; van Rooij R; Smits MLJ; Bruijnen RCG; Prince JF; Bol GM; de Jong HWAM; Lam MGEH
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):443-450. PubMed ID: 38326577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of imaging
    Kunnen B; Dietze MMA; Braat AJAT; Lam MGEH; Viergever MA; de Jong HWAM
    Med Phys; 2020 Mar; 47(3):1105-1114. PubMed ID: 31855282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization.
    Wondergem M; Smits ML; Elschot M; de Jong HW; Verkooijen HM; van den Bosch MA; Nijsen JF; Lam MG
    J Nucl Med; 2013 Aug; 54(8):1294-301. PubMed ID: 23749996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
    Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
    J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.
    Ilhan H; Goritschan A; Paprottka P; Jakobs TF; Fendler WP; Todica A; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2015 Nov; 56(11):1654-60. PubMed ID: 26315830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment.
    Ahmadzadehfar H; Sabet A; Biermann K; Muckle M; Brockmann H; Kuhl C; Wilhelm K; Biersack HJ; Ezziddin S
    J Nucl Med; 2010 Aug; 51(8):1206-12. PubMed ID: 20660379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT.
    Chansanti O; Jahangiri Y; Matsui Y; Adachi A; Geeratikun Y; Kaufman JA; Kolbeck KJ; Stevens JS; Farsad K
    J Vasc Interv Radiol; 2017 Nov; 28(11):1528-1535. PubMed ID: 28888827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A Prospective Single-Arm Clinical Trial.
    Kokabi N; Webster LA; Elsayed M; Switchenko JM; Chen B; Brandon D; Galt J; Sethi I; Cristescu M; Kappadath SC; Schuster DM
    J Vasc Interv Radiol; 2022 Dec; 33(12):1578-1587.e5. PubMed ID: 36075560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
    Lam MG; Goris ML; Iagaru AH; Mittra ES; Louie JD; Sze DY
    J Nucl Med; 2013 Dec; 54(12):2055-61. PubMed ID: 24144563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization.
    Heusner TA; Hamami ME; Ertle J; Hahn S; Poeppel T; Hilgard P; Bockisch A; Forsting M; Antoch G
    Rofo; 2010 Jul; 182(7):603-8. PubMed ID: 20183775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of repeat angiographic assessment in patients designated for radioembolization using yttrium-90 microspheres with initial extrahepatic accumulation of technitium-99m macroaggregated albumin: a single center's experience.
    Dudeck O; Wilhelmsen S; Ulrich G; Löwenthal D; Pech M; Amthauer H; Ricke J
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1083-93. PubMed ID: 21833803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial.
    Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Huijbregts JE; van het Schip AD; Elschot M; Bult W; de Jong HW; Meulenhoff PC; Zonnenberg BA
    J Exp Clin Cancer Res; 2010 Jun; 29(1):70. PubMed ID: 20550679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
    Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
    J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.